Iris Friedli (Senior MRI Director) and Paul Hockings (Senior Scientific Advisor) from Antaros Medical are joining the conversation on kidney MRI and its potential in drug development at the 6th International RenalMRI Meeting in Pamplona, Spain, October 13–14, 2025.
Their presentation, “Expanding Horizons: MRI in Kidney Disease Drug Development,” explores the urgent need for better biomarkers to accelerate drug development for kidney conditions such as Chronic Kidney Disease (CKD), Diabetic Kidney Disease (DKD), and Polycystic Kidney Disease (PKD). Current development is hampered by lengthy, large-scale trials and biomarkers that fail to capture the full complexity of these diseases.
MRI is already transforming trials in ADPKD and CKD by delivering precise, reproducible measurements across global sites. Unlike traditional endpoints, imaging can detect subtle disease progression, measure treatment effects earlier, and provide whole-organ insights that complement biomarkers like eGFR and proteinuria.
Don’t miss their talk today, October 14, at 16:20.